Table I.
P-value | |||||||
---|---|---|---|---|---|---|---|
Group | n | Median survival time (h) | Interquartile range (h) | Compared with the SAP group | Compared with the IU group | Compared with the SL group | |
SAP | 10 | 4.83 | 2.83–8.50 | ||||
IU | 10 | 6.67 | 5.50–9.50 | 0.044a | |||
SL | 10 | 6.17 | 5.33–8.33 | 0.370 | 0.267 | ||
LUL | 10 | 8.17 | 5.25–12.00 | 0.003b | 0.046a | 0.011a | |
MUL | 10 | 9.50 | 6.25–12.00 | 0.000b | 0.002b | 0.000b | |
HUL | 10 | 8.75 | 6.00–12.00 | 0.000b | 0.040a | 0.001b | |
UHUL | 10 | 7.67 | 4.25–11.25 | 0.015a | 0.352 | 0.034a |
P<0.05
P<0.01. SAP, severe acute pancreatitis; IU, intravenous ulinastatin (2,500 U/100g); SL, saline lavage; LUL, low-dose ulinastatin lavage (25 U/ml); MUL, medium-dose ulinastatin lavage (62.5 U/ml); HUL, high-dose ulinastatin lavage (125 U/ml); UHUL, ultra-high-dose ulinastatin lavage (250 U/ml).